نتائج البحث - "Vera E R Asscher"

1

دورية أكاديمية

Longitudinal study of changes in γδ T cells and CD4+ T cells upon asymptomatic malaria infection in Indonesian children

المؤلفون: Sanne E. de Jong, Vera E. R. Asscher, Linda J. Wammes, Aprilianto E. Wiria, Firdaus Hamid, Erliyani Sartono, Taniawati Supali, Hermelijn H. Smits, Adrian J. F. Luty, Maria Yazdanbakhsh

المصدر: Scientific Reports, Vol 7, Iss 1, Pp 1-7 (2017)

مصطلحات موضوعية: Medicine, Science

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2045-2322

URL الوصول: https://doaj.org/article/7d52068d2c9941339627fa2d9bd14787

Find this article in full text from ProQuest

Full Text Finder

2

Deficits in geriatric assessment associate with disease activity and burden in older patients with inflammatory bowel disease

المساهمون: RS: FHML non-thematic output, MUMC+: MA Maag Darm Lever (9), KNO

المصدر: Clinical Gastroenterology and Hepatology, 20(5), E1006-E1021. ELSEVIER SCIENCE INC
Clinical gastroenterology and hepatology, 20(5), E1006-E1021. Elsevier Science

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::572bc15b64a46714ae79cc50013493c2
https://hdl.handle.net/1887/3503747

View record from ScienceDirect

Full Text via ClinicalKey

3

Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events

المؤلفون: Bas A. C. van Tuyl, Marieke Pierik, Vera E. R. Asscher, P W Jeroen Maljaars, Bas Oldenburg, Anniek M. van der Aalst, Andrea E. van der Meulen-de Jong, Dutch Icc, Eelco C. Brand, Nofel Mahmmod, Karen van der Aalst, Herma H. Fidder, Quirine M.J. van der Vliet

المساهمون: RS: NUTRIM - R2 - Liver and digestive health, MUMC+: MA Maag Darm Lever (9)

المصدر: International Journal of Colorectal Disease
International Journal of Colorectal Disease, 35(12), 2331-2338. SPRINGER
International Journal of Colorectal Disease, 35(12), 2331-2338. Springer, Cham

مصطلحات موضوعية: Crohn’s disease, Male, medicine.medical_specialty, Co-morbidity, Comorbidity, Biologicals, Inflammatory bowel disease, 03 medical and health sciences, 0302 clinical medicine, Elderly, Internal medicine, INFLIXIMAB, medicine, Humans, Adverse effect, ELDERLY-PATIENTS, Aged, Retrospective Studies, RISK, Crohn's disease, Proportional hazards model, business.industry, Tumor Necrosis Factor-alpha, Gastroenterology, ANTI-TNF THERAPY, CHEMOTHERAPY, medicine.disease, Inflammatory Bowel Diseases, Ulcerative colitis, CANCER, Infliximab, CROHNS-DISEASE, Anti-Tumor Necrosis Factor Therapy, INFECTIONS, 030220 oncology & carcinogenesis, SAFETY, 030211 gastroenterology & hepatology, Original Article, Female, business, medicine.drug, COLITIS

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e38666bfc82218187a355af8fde9b48b
https://cris.maastrichtuniversity.nl/en/publications/e92f6606-f495-47b1-9535-c069cf7f826d

Find this article in full text from Springer Verlag.

4

Editorial: is age just a number when it comes to treatment of inflammatory bowel disease? Authors' reply

المؤلفون: Vera E R, Asscher, Vince B C, Biemans, Frank, Hoentjen, P W Jeroen, Maljaars

المصدر: Alimentary pharmacologytherapeuticsREFERENCES. 52(10)

مصطلحات موضوعية: Cohort Studies, Humans, Ustekinumab, Comorbidity, Prospective Studies, Antibodies, Monoclonal, Humanized, Inflammatory Bowel Diseases

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::859ef8150967b0210b919effe4ad3506
https://pubmed.ncbi.nlm.nih.gov/33085983

View record at Wiley

5

Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study

المؤلفون: Rinse K. Weersma, Alexander Bodelier, Mark Löwenberg, Jeoffrey J L Haans, P W Jeroen Maljaars, Willemijn A van Dop, Colitis (Icc), Frank Hoentjen, Marieke Pierik, Nanne K. H. de Boer, Jeroen M. Jansen, Gerard Dijkstra, Vince B. C. Biemans, Rachel L. West, Vera E R Asscher, Dutch Initiative on Crohn, Sander van der Marel

المساهمون: Translational Immunology Groningen (TRIGR), Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Groningen Institute for Organ Transplantation (GIOT), Gastroenterology and hepatology, AGEM - Digestive immunity, AII - Inflammatory diseases, Interne Geneeskunde, RS: NUTRIM - R2 - Liver and digestive health, MUMC+: MA Maag Darm Lever (9), Gastroenterology and Hepatology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism

المصدر: Alimentary Pharmacology & Therapeutics, 52(8), 1366-1376. Wiley
Alimentary Pharmacology & Therapeutics, 52, 8, pp. 1366-1376
Alimentary Pharmacology and Therapeutics
Alimentary Pharmacology & Therapeutics
Alimentary Pharmacology and Therapeutics, 52(8), 1366-1376
Alimentary Pharmacology & Therapeutics, 52, 1366-1376
Alimentary pharmacology & therapeutics, 52(8), 1366-1376. Wiley-Blackwell
Alimentary Pharmacology and Therapeutics, 52(8), 1366-1376. WILEY
Dutch Initiative on Crohn and Colitis (ICC) 2020, ' Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab-and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study ', Alimentary Pharmacology and Therapeutics, vol. 52, no. 8, pp. 1366-1376 . https://doi.org/10.1111/apt.16073

مصطلحات موضوعية: MAINTENANCE THERAPY, medicine.medical_specialty, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], Inflammatory bowel disease, Vedolizumab, 03 medical and health sciences, 0302 clinical medicine, Maintenance therapy, Internal medicine, Ustekinumab, medicine, Pharmacology (medical), 030212 general & internal medicine, Adverse effect, ELDERLY-PATIENTS, RISK, Original Scientific Paper, Efficacy and Safety of Biologics for Crohn's Disease, Hepatology, business.industry, INDUCTION, Confounding, Gastroenterology, medicine.disease, Comorbidity, 030211 gastroenterology & hepatology, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], Cohort study, medicine.drug